tiprankstipranks
Trending News
More News >

Hemogenyx Pharmaceuticals Secures Funding for Clinical Trials

Story Highlights
Hemogenyx Pharmaceuticals Secures Funding for Clinical Trials

Confident Investing Starts Here:

The latest announcement is out from HemoGenyx Pharmaceuticals Plc ( (GB:HEMO) ).

Hemogenyx Pharmaceuticals has raised £451,250 to continue its Phase 1 clinical trials for its Chimeric Antigen Receptor T-cell therapy, HG-CT-1, targeting relapsed/refractory acute myeloid leukemia in adults. This funding, secured at a premium, reflects investor confidence in the company’s long-term potential and allows the advancement of their pivotal therapy without significant dilution, potentially strengthening their position in the biopharmaceutical industry.

More about HemoGenyx Pharmaceuticals Plc

Hemogenyx Pharmaceuticals is a publicly traded clinical stage biopharmaceutical company based in London, with US subsidiaries in New York City. The company focuses on developing new medicines and treatments for blood and autoimmune diseases, leveraging platform technologies for novel product development.

Average Trading Volume: 40,185

Technical Sentiment Signal: Sell

Current Market Cap: £7.59M

Find detailed analytics on HEMO stock on TipRanks’ Stock Analysis page.

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.

Report an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1